Responses
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
FRI0187 A Randomized Crossover Comparison of Injection Site Pain with 40 Mg/0.8 Ml and 40 mg/0.4 ml Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.